Using a deep learning tool slices reading time by nearly 75 percent and makes disease identification easier.
Using artificial intelligence (AI) with coronary CTA scans can make it easier for radiologist to identify obstructive coronary artery disease.
In a study published recently in the European Journal of Radiology, investigators from China detailed how using AI not only speeds up post-processing and interpretation times for these scans, but it can pinpoint abnormalities in major arteries that contribute to the disease.
Evaluating stenosis can be difficult, the team said, making proper training and experience important for proper image interpretation.
“Thus, AI software as a second reader may substantially shorten reading time, potentially improve the diagnostic accuracy of inexperienced readers, and increase the confidence of more experienced readers,” said the team led by Chun Yu Liu of the Jinling Hospital’s diagnostic radiology department in Nanjing China.
To reach this goal and automate the process, they pulled data from 165 patients to develop a deep-learning tool. They, then, looked at its solo performance in comparison to radiologists who read alone and those who read with the AI tool. They defined coronary artery disease (CAD) as luminal stenosis of 50 percent or more and used invasive coronary angiography for a reference standard.
Based on their analysis, AI alone diagnosed obstructive CAD with 90.5 percent sensitivity, 82.3 percent specificity, and an area under the curve of 0.90. When using the tool, radiologists saw their post-processing time drop from 8.5 minutes to 3.7 minutes.
Liu’s team noted that image quality and arterial calcification didn’t affect the software’s performance, pointing to its potential for utilization.
“Image quality and calcification burden did not negatively affect the diagnostic performance of AI,” they said. “Thus, AI may be an efficient tool for the diagnosis of coronary artery stenosis.”
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.